Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?
SA Analyst Upgrades: PFE, ALLY, TMUS, ECC, CRK
Price Over Earnings Overview: Eli Lilly
Option Care Health Upgraded at UBS on Valuation After Q1 Beat
Market Whales and Their Recent Bets on LLY Options
Pfizer Analyst Ratings
Eli Lilly Q1 2025 Earnings Preview
Johnson & Johnson Receives FDA Approval For IMAAVYTM, A New FcRn Blocker Offering Long-Lasting Disease Control In The Broadest Population Of People Living With Generalized Myasthenia Gravis
Dow Surges 300 Points Amid Trade Deal Hopes: Greed Index Remains In 'Fear' Zone
Is it all Trump's fault for wildly swinging the 'tariff club'? Pfizer: Uncertainty has hindered manufacturing and research and development investment.
① Pfizer CEO Albert Bourla stated that the uncertainty surrounding Trump's proposed pharmaceutical tariffs is hindering the company's manufacturing and R&D investments in the USA; ② Bourla emphasized that the company hopes to see "certainty," meaning clear tariffs or additional incentives, to increase investment in the USA.
Earnings Call Summary | Pfizer(PFE.US) Q1 2025 Earnings Conference
Pfizer Targets $7.7B in Operational Efficiency Savings by 2027, Highlights Strategic R&D Shifts
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum
Pfizer Shares Are Trading Higher Following a Q1 EPS Beat. The Company Reaffirmed Guidance but Said It Is Trending Towards the Upper End of Its 2025 Adjusted Diluted EPS Guidance Range.
Dow Boosted by Honeywell, Sherwin-Williams While S&P and Nasdaq Seesaw
Sandoz Inks Agreement With Shanghai Henlius for Bristol Yervoy Biosimilar
Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts
WeightWatchers Rises on Partnership With Eli Lilly to Enhance Zepbound Access
4 Stocks to Watch on Tuesday: KO, PFE, GM and UPS